


## Desmethyl Levofloxacin-d<sub>8</sub> hydrochloride

<b>Cat. No.:</b>	HY-135389S
<b>CAS No.:</b>	1217677-38-7
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>11</sub> D <sub>8</sub> ClFN <sub>3</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	391.85
<b>Target:</b>	Drug Metabolite; Antibiotic; Isotope-Labeled Compounds
<b>Pathway:</b>	Metabolic Enzyme/Protease; Anti-infection; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Desmethyl Levofloxacin-d8 hydrochloride is the deuterium labeled Desmethyl Levofloxacin. Desmethyl Levofloxacin is a metabolite of Levofloxacin. Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication <sup>[1]</sup> .
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. *Int J Chron Obstruct Pulmon Dis*, 2014. 9: p. 179-86.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA